Oncology drug developers must start asking questions in preparation of FDA’s dose optimization initiative.
Julie Bullock
Advertisement
SVP, Clinical Pharmacology & Translational Medicine
Articles by Julie Bullock
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
The Industry’s Communication and Engagement with FDA
2
Pharma Roundup: Bristol Myers Squibb Enters Strategic Agreement with Anthropic, Incyte and Genesis Expand Strategic Collaboration
3
Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio
4
FDA Makes Leadership Overhaul Following Commissioner Makary’s Departure: Report
5